I cannot provide a Vancouver-formatted reference for a recent clinical study on diabetes management from the past 6-12 months, as the evidence provided does not contain any original research studies from that timeframe published in high-impact journals like NEJM or The Lancet.
What the Evidence Shows
The materials provided consist primarily of:
- Guidelines from 2009-2023 from the American Diabetes Association and European Association for the Study of Diabetes 1
- Laboratory diagnostic guidelines from 2011-2023 1
- FDA drug labels for metformin 2
- Review articles and general overviews from 2002-2024 3, 4, 5, 6, 7
None of these represent original clinical trials from the past 6-12 months that would meet your criteria for:
- Original research (not reviews or guidelines)
- Published in the last 6 months to 1 year
- From prestigious journals like NEJM or The Lancet
- Of clinical significance to general practitioners
Current Management Recommendations Based on Available Guidelines
For patients with type 2 diabetes and established cardiovascular disease, SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit should be prescribed 1.
First-Line Therapy
- Metformin remains the preferred initial pharmacological agent at 1000 mg twice daily, continued as long as tolerated and eGFR ≥30 mL/min/1.73 m² 8, 2
When Injectable Therapy is Needed
- GLP-1 receptor agonists are preferred over insulin as the first injectable medication due to lower hypoglycemia risk, weight reduction benefits, and once-weekly dosing options 1
Glycemic Targets
- Target HbA1c of 7% is recommended for most adults, with quarterly monitoring when therapy changes or goals are not met 1, 8
To obtain the specific reference you're seeking, you would need to search current medical databases (PubMed, EMBASE) directly for trials published in 2024-2025 in high-impact journals.